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Early-onset Alzheimer’s disease (EOAD) represents 1%e2% of the Alzheimer’s disease (AD) cases, and it is
generally characterized by a positive family history and a rapidly progressive symptomatology. Rare
coding and fully penetrant variants in amyloid precursor protein (APP), presenilin 1 (PSEN1), and pre-
senilin 2 (PSEN2) are the only causative mutations reported for autosomal dominant AD. Thus, in this
study we used exome sequencing data to rapidly screen rare coding variability in APP, PSEN1, and PSEN2,
in a British cohort composed of 47 unrelated EOAD cases and 179 elderly controls, neuropathologically
proven. We report 2 novel and likely pathogenic variants in PSEN1 (p.L166V and p.S230R). A compre-
hensive catalog of rare pathogenic variants in the AD Mendelian genes is pivotal for a premortem
diagnosis of autosomal dominant EOAD and for the differential diagnosis with other early onset de-
mentias such as frontotemporal dementia (FTD) and Creutzfeldt-Jakob disease (CJD).
 2014 The Authors. Published by Elsevier Inc. All rights reserved.e CC BY license (http://
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Early-onset Alzheimer’s disease (EOAD), with onset of symp-
toms before 65 years of age, accounts for 1%e2% of the Alzheimer’s
disease (AD) cases. The disease commonly clusters within families
and presents a rapid and severe progression. Generally, EOAD is a
polygenic and complex disease. On the contrary, 10% of EOAD cases
present a Mendelian autosomal dominant pattern of inheritance
and are caused by rare and fully penetrant mutations in amyloid
precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2
(PSEN2), leading to Aß42 overproduction (Goate et al., 1991; Pastor
and Goate, 2004; Raux et al., 2005; Sherrington et al., 1995).
PSEN1 is the most common cause of EOAD (18%e50%), with 185
mutations reported (www.molgen.database/). By contrast, APP and
PSEN2 have been described in 5% and <1% of the EOAD cases,
respectively (www.molgen.database/). Given the pivotal role of
these genes in AD pathogenesis, a detailed catalog of pathogenic
variants and an algorithm for their classiﬁcation are fundamental
premises for an effective genetic screening of the patients.ts reserved.
C. Sassi et al. / Neurobiology of Aging 35 (2014) 2422.e13e2422.e162422.e142. Methods
2.1. Cases and controls
Our cohort was composed of 47 independent EOAD (age at onset
65 years) autopsy proven cases and 179 elderly (>60 years), un-
related controls. Three patients reported a positive family history of
AD. The other patients were referred as apparently sporadic EOAD
cases.
All the patients and controls were Caucasian, mostly from the
UK (London, Manchester, Nottingham, and Edinburgh) and to a
lesser extent from North America. The average age at diagnosis was
57.7 years (range 41e64 years) for the EOAD patients and the mean
age of ascertainment was 78 years (range 60e102 years) for the
controls (Table 1).
Written informed consent was obtained for each individual and
the study was approved by the appropriate institutional review
boards.
2.2. Exome sequencing
Library preparation for next-generation sequencing was per-
formed according to the NimbleGen (Roche NimbleGen v2) and
TruSeq (Illumina) sample-preparation protocols. DNA libraries were
then hybridized to exome-capture probes with NimbleGen SeqCap
EZ Human Exome Library, version 2.0 (Roche NimbleGen) or TruSeq
(Illumina). Each capture method covers the APP, PSEN1, and PSEN2
loci. Exome-enriched libraries were sequenced on the Illumina
HiSeq 2000 using 2  100 bp paired end read cycles.
2.3. Bioinformatics
Sequence alignment and variant calling was performed against
the reference human genome (UCSC hg19). Paired end sequence
reads (2  100 bp paired end read cycles) were aligned using the
Burrows-Wheeler aligner (Li and Durbin, 2009). Format conversion
and indexing were performed with Picard (www.picard.sourceforge.
net/index.shtml). The Genome Analysis Toolkit was used to recali-
brate base quality scores, perform local re-alignments around indels,
and to call and ﬁlter the variants (McKenna et al., 2010). VCFtools was
used to annotate gene information for the remaining novel variants.
In total, 450,987 single-nucleotide variants and 41,678 indels were
called. We used snpEff v3.2 software to annotate the variants. Vari-
ants were checked against established databases (1000 Genomes
Project and dbSNP v.134). The protein coding effects of variants was
predicted using SIFT, Polyphen2, and SeattleSeq Annotation (gvs.gs.
washington.edu/SeattleSeqAnnotation). All variants within the cod-
ing regions of APP, PSEN1, and PSEN2 were annotated for both cases
and controls.
2.4. Sanger sequencing
All rare variants identiﬁed by whole-exome sequencing in the
candidate genes were validated by Sanger sequencing.
Primers for exons harboring rare variants were designed in
Primer3 (http://bioinfo.ut.ee/primer3-0.4.0/) using UCSC (http://Table 1
Cohort
Cohort n Diagnosis Sequencing stra
EOAD 47 Clinical and neuropathological Exome sequenc
Controls 179 Clinical and neuropathological Exome sequenc
Key: EOAD, early-onset Alzheimer’s disease; SD, standard deviation.genome.ucsc.edu/) reference sequences NM_000484 (APP),
NM_000021.3 (PSEN1), and NM_000447.2 (PSEN2).
Puriﬁed sequences were analyzed on an ABI 3730 DNA Analyzer
(Applied Biosystems, CA, USA) and electropherograms were visu-
alized in Sequencher software (version 4.2 Gene Codes Corporation,
MI, USA).
2.5. Apoe genotyping
APOE genotypes comprising the APOE 32, 3 , and 34 alleles were
assayed using the TaqMan method (Applied Biosystems Inc [ABI],
Foster City, CA, USA). Single nucleotide polymorphisme speciﬁc
primers and probes were designed by ABI (TaqMan genotyping
assays).
3. Results
We report the experience of a mutation screening in APP, PSEN1,
and PSEN2 in 47 EOAD unrelated cases and 179 elderly controls
neuropathologically proven, from the UK. 9 EOAD cases (19%) and 5
controls (2.8%) carried at least 1 rare coding variant in the genes
studied.
In our EOAD cohort, we identiﬁed a total of 8 rare coding vari-
ants in APP, PSEN1, and PSEN2, absent in controls. Of these, 3 have
been previously reported in familial AD (p.C410Y and p.113þ1delG
in PSEN1 and p.V717L in APP) (Campion et al., 1995; De Jonghe et al.,
2001; Murrell et al., 2000; Tysoe et al., 1998) and 4 are novel var-
iants: 2 detected in PSEN1 (p.L166V and p.S230R) and 2 in APP
(p.K496Q and p.620L). In addition, we report a rare and likely
tolerated polymorphism in PSEN2 (p.S130L, rs63750197), present in
1 case and 1 control (Table 2).
PSEN1 p.L166V maps to the third transmembrane domain (TM3)
of PS1, on the a-helix surface and corresponds to a conserved
domain in PSEN2 (p.L172), where no variants or mutations have
been reported. Moreover, it has been described as possibly
damaging by in silico predictions (SIFT and Polyphen2). This variant
was detected in a very early onset case, presenting typical and
rapidly progressing AD features with extrapyramidal signs
(parkinsonism and myoclonus). At the age of 42 years, this patient
developed difﬁculties in memory, necessitating his retirement from
work. Over the next 2 years, he presented a decline in cognitive
function, culminating in his medical referral. His memory loss had
become more severe, he had difﬁculties in verbal expression,
reading, writing, and calculation, and he was spatially disoriented.
He had become generally apathetic. Neurologic examination
revealed extrapyramidal signs and myoclonus. Neuropsychological
examination revealed profound impairments in memory, language,
perceptuospatial skills, and praxis. Social skills werewell preserved,
and he was frustrated by his difﬁculties.
He was reviewed at regular intervals over the following 4 years.
During that time there was dramatic decline in his physical and
cognitive skills. He showed marked parkinsonism and myoclonus.
Speech was unintelligible, and he showed profound perceptual and
spatial impairments. A single photon emission computerized to-
mography (SPECT) scan, 4 years after symptom onset, showed
temporoparietal hypoperfusion. The proﬁle remained typical of
Alzheimer’s disease. He died aged 50 years, 8 years after onset oftegy Age (y) mean  SD (range) Male (%) APOE e4þ (%)
ing 57.7 (41e64) 55 57
ing 78 (60e102) 55 40
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C. Sassi et al. / Neurobiology of Aging 35 (2014) 2422.e13e2422.e16 2422.e15symptoms. The neuropathological examination revealed advanced
AD lesions (Braak VI, CERAD C). There was no relevant previous
medical history and no clear history of dementia in any ﬁrst-degree
relative, still alive, and in good health conditions.
Finally, the PSEN1 p.L166V was not found in 179 healthy elderly
neuropathologically conﬁrmed controls, or in any control present in
genomic variant databases (dbSNP v.137, ESP).
PSEN1 p.S230R is a nonconservative amino acid change in the
ﬁfth transmembrane domain (TM5), on the a-helix surface of PS1. It
corresponds to a conserved residue in PSEN2 (p.S236), where no
variants or mutations have been described and was predicted as
possibly damaging by SIFT and Polyphen2. The carrier presented
features consistent with the reported clinical phenotype in most
PSEN1 mutations. The patient was diagnosed at 58 years, with a
2-year history of problems in memory. Neurologic examinationwas
entirely normal. His behavior was socially appropriate and he was
insightful into his difﬁculties. Neuropsychological examination
conﬁrmed the problems in memory and language. Performance in
other cognitive domains was well preserved. Functional imaging
using SPECT showed left posterior hypoperfusion. The patient’s
father had died in his early 60s of a similar dementing illness. The
patient was clinically diagnosed with Alzheimer’s disease, which
was suspected to be familial.
He was reviewed at regular intervals. His cognitive skills dete-
riorated gradually. His memory became worse; he had increased
difﬁculties in verbal expression and visuospatial tasks. He pre-
sented parkinsonian signs and myoclonus. A repeat SPECT scan
revealed bilateral parietal hypoperfusion, more marked on the left
side. Latterly, he became severely parkinsonian and mute. He died
aged 66 years, 10 years after onset of symptoms. The neuropatho-
logical features revealed a fully developed Alzheimer’s disease
(Braak VI, CERAD C).
Finally, although we cannot rule out a pathogenic role for APP
p.K496Q and p.620L, we suggest they are likely to be rare benign
polymorphisms, as they cluster outside exon 16 and 17, where all
pathogenic mutations have been reported up to date (www.
molgen.database/).
4. Discussion
Mutations in APP, PSEN1, and PSEN2 are the only fully penetrant
variants described for EOAD. Thus, in this study we used exome-
sequencing data to investigate rare coding variability in APP,
PSEN1, and PSEN2, in a British cohort composed of 47 unrelated
EOAD cases and 179 elderly controls. In this cohort, 6 patients of 47
(12.7%) and none of the controls carried a rare coding variant in
PSEN1. This conﬁrms that PSEN1 is the major gene involved in EOAD
and suggests that rare coding variability in this gene is commonly
detrimental. Among the variants detected in PSEN1, 2 are novel
(p.L166V and p.S230R), likely harmful and classiﬁed as probable
pathogenic, following the algorithm proposed by Guerreiro et al.
(2010). These variants have been detected in 2 patients who pre-
sented the typical hallmarks of PSEN1 mutations: early onset of
symptoms, aggressive symptomatology, and extrapyramidal signs
(parkinsonism and myoclonus).
PSEN1 p.L166 codon seems to be a very vulnerable site for mu-
tations: 4 different causal mutations (p.L166del, p.L166H, p.L166P,
and p.L166R) have been previously described in this same residue in
3 familial AD cases (p.L166R, p.L166P, and p.L166del) (Ezquerra
et al., 2000; Knight et al., 2007; Moehlmann et al., 2002) and in 1
pseudo-sporadic case (p.L166H) (Pantieri et al., 2005). From these,
p.L166P is known to be a very aggressive mutation: it causes onset
of symptoms before the third decade of age, signiﬁcantly increases
Ab42 production, and impairs NOTCH1 signaling in a cell culture
system (Moehlmann et al., 2002). Furthermore, the amino acid
C. Sassi et al. / Neurobiology of Aging 35 (2014) 2422.e13e2422.e162422.e16position 166, located in the TM3 of PS1 shows a signiﬁcant phylo-
genetic conservation across different species and in homologous
proteins such as PS2, suggesting that the position is of functional
signiﬁcance.
In our cohort, the PSEN1 p.L166V variant has been detected in a
patient with very young onset of age (42 years at diagnosis), thus
supporting the severe effects of an amino acid substitution in this
conserved residue. Surprisingly, the patient’s parents were not
affected by Alzheimer’s disease. This suggests that the p.L166V may
be a de novo mutation or that other genetic factors may inﬂuence
the phenotype of PSEN1 mutations.
PSEN1 p.S230R clusters in the TM5 domain of PS1 and is the
homologous of a conserved residue in PSEN2 (p.S236). The patient
carrying this variant presented a family history of AD. Recently, a
different missense mutation in this codon (p.S230I) has been re-
ported as possible pathogenic in a French family with EOAD
(Wallon et al., 2012). Thus, the p.S230R is likely to be a novel mu-
tation for early onset, autosomal dominant Alzheimer’s disease.
In summary, we conﬁrm that PSEN1 is commonly associated
with EOAD and we report 2 novel and likely pathogenic mutations
detected in this gene (p.L166V and p.S230R). A comprehensive
catalog of rare pathogenic variants in Alzheimer’s disease Mende-
lian genes is pivotal: (1) for a premortem diagnosis of EOAD pa-
tients; (2) for the differential diagnosis of other types of early onset
dementias (FTD and CJD); and (3) for the identiﬁcation of at risk
relatives who may be potential candidates for clinical trials.
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